As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.
Read the special edition of Science « Completing the human genome » >
Human Genome - Genoscope Human Genome - Genoscope

The first—mostly complete—sequence of the human genome, of which chromosome 14 was decoded in France by Genoscope, was published eleven years ago, and the adventure continues today. Indeed, in an article dated 31 March 2022 and earning the cover of the 1 April edition of Science, the international Telomere-to-Telomere Consortium reported sequencing the 8% of the human genome that had remained unaddressed. Genopole Research & Platforms Director Christophe Lanneau discusses this important advancement.

Under the codename GRCh38, the most recent human genome reference sequence represented a consensus of several different genomes that had progressively enriched the very first sequence established in 2001. Despite that headway, 8% of the human genome had remained inaccessible because it was composed of highly-repetitive sequences that eluded discrimination and ordering by sequencing techniques*.

Today however, using novel sequencing technologies able to read very long sequences, the Telomere-to-Telomere consortium has filled in those holes. That consortium was created in 2019 with the objective of gaplessly reading each chromosome from one end (the “telomere”) to the other.

Genopole Research & Platforms Director CitationChristophe Lanneau, analyzes this major scientific breakthrough:
« This new human genome reference assembly, called CHM13, provides a very precise map of the highly-repetitive DNA sequences. It determined more than 225 million additional base pairs in a genome counting 3.1 billion. These highly-repetitive regions had remained inaccessible and received insufficient attention for many years. However, we’ve now come to realize their importance in cellular function and some of their roles in disease. This work is a major step forward for science.

These repetitive sequences are found mainly in two key regions of the chromosome: the centromere, a central region that plays a role in cell division and the correct transmission of the chromosome to the daughter cell, and the telomeres, the ends of the chromosome, that shorten as cells age and thus regulate their lifespans.

Being able to explore these sequences will yield new discoveries as to the genetic diversity they contain. These previously hidden sequences are also involved in epigenetic modifications. Epigenetics describes reversible and potentially inheritable mechanisms able to modify gene expression without modifying the underlying code. Epigenetics adapts gene expression to the environment or cell function. An increasing amount of evidence supports its role in organism function and adaptation.

Thus, with the rapidity of Illumina’s next-generation sequencing technology, researchers will be able to generate genomes in a matter of hours while benefiting in parallel from the quality and exhaustivity of this new reference sequence to better understand and interpret DNA sequences. »

In an interview with the newspaper Le Figaro, Citationthe director of the National Center of Human Genomics Research Jean-François Deleuze, underlines the importance of this work for «understanding key biological mechanisms.» He adds:«With current sequencing methods, we understand only about 50% of genetic diseases. Now, we may finally be able to better explain certain orphan diseases.»

In conclusion

Having a nearly-totally complete sequence of the human genome will contribute immeasurably to a better understanding not only of human evolution and cellular multiplication & differentiation but also of a range of diseases including cancers, cardiovascular diseases and many more.
Progress remains necessary in the determination of individual genetic diversity in human populations and the exploration of the y chromosome (resulting in male sex), which, for technical reasons, remains out of the reach of the technology deployed in the study.

  • * Genome sequencing technologies

    Genome sequencing describes the determination of the specific order of the “bases” (adenine (A), cytosine (C), guanine (G), and thymine (T)) that constitute the DNA sequence. Next-generation sequencing (NGS), developed notably by Illumina, involves cutting the genome into small fragments of about 100 base pairs then reading them individually. Because the cuts do not occur in the same place across different cells, the identification of identical sequence ends enables the reassembly and reconstitution of the DNA sequence via computerized analysis.

    More recently, the Oxford Nanopore technology has made it possible to read sequences with several tens of thousands of base pairs and even more. This technology involves forcing the passage of a DNA fragment through a nanometer-wide pore carrying an electrical current, which is modified in a specific manner by the passage of each base (A, C, G or T). Those current modifications progressively reveal the DNA sequence.

    Pacific Biosciences’ technology is also able to read sequences of at least 20,000 base pairs with 99.9% precision.


Special edition of Science « Completing the human genome »

Article posted on 4 April 2022


The latest news

©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

View all >
With the support from
Région île de France